Austin Health

Title
Lab-in-a-van: Rapid SARS-CoV-2 testing response with a mobile laboratory.
Publication Date
2022-05
Author(s)
Ballard, Susan A
Graham, Maryza
David, Debra
Hoang, Tuyet
Donald, Angela
Sait, Michelle
Isles, Nicole
Matlock, Amelia
Yallop, Sarah
Bek, Mark
Howden, Benjamin P
Stinear, Timothy P
Subject
Mobile testing
Point-of-care
Rapid testing
Real-time PCR
SARS-CoV-2
Turnaround-time
Type of document
Journal Article
OrcId
0000-0003-0237-1473
DOI
10.1016/j.ebiom.2022.103983
Abstract
High testing rates and rapid contact tracing have been key interventions to control COVID-19 in Victoria, Australia. A mobile laboratory (LabVan), for rapid SARS-CoV-2 diagnostics, was deployed at sites deemed critical by the Victorian State Department of Health as part of the response. We describe the process of design, implementation, and performance benchmarked against a central reference laboratory. A BSL2 compliant laboratory, complete with a class II biological safety cabinet, was built within a Mercedes-Benz Sprinter Panel Van. Swabs were collected by on-site collection teams, registered using mobile internet-enabled tablets and tested using the Xpert® Xpress SARS-CoV-2 assay. Results were reported remotely via HL7 messaging to Public Health Units. Patients with negative results were automatically notified by mobile telephone text messaging (SMS). A pilot trial of the LabVan identified a median turnaround time (TAT) from collection to reporting of 1:19 h:mm (IQR 0:18, Range 1:03-18:32) compared to 9:40 h:mm (IQR 8:46, Range 6:51-19:30) for standard processing within the central laboratory. During deployment in nine rural and urban COVID-19 outbreaks the median TAT was 2:18 h:mm (IQR 1:18, Range 0:50-16:52) compared to 19:08 h:mm (IQR 5:49, Range 1:36-58:52) for samples submitted to the central laboratory. No quality control issues were identified in the LabVan. The LabVan is an ISO15189 compliant testing facility fully operationalized for mobile point-of-care testing that significantly reduces TAT for result reporting, facilitating rapid public health actions. This work was supported by the Department of Health, Victoria State Government, Australia.
Link
Citation
EBioMedicine 2022; 79: 103983
Jornal Title
EBioMedicine

Files:

NameSizeformatDescriptionLink